The immune tolerance that occurs during tumour immunotherapy may be related to the overexpression of suppressive counter-receptors (e.g., PDL1 and PDL2) by m2 macrophages that suppress the body’s immune function (Pushalkar et al., 2018). The gene discussed is PDCD1LG2; the disease is neoplasm.